Senti Bio reports encouraging SENTI-202 AML trial results as the FDA grants RMAT status, with strong response rates, durable ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high ...
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...
Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating ...
The Logic Class II, Type A2 Biosafety Cabinets (BSCs) provide full personnel, product, and environmental protection from hazardous particulates, including those requiring BSL 1–4 containment. They are ...
FREDERICK, MD, UNITED STATES, July 30, 2025 /EINPresswire.com/ -- VaLogic Bio has acquired Air Systems Technologies (AST), expanding the services available to life ...
The Insider is Venture Partners at CU Boulder's monthly newsletter featuring the latest headlines, news, events, opportunities and emerging innovations from the university. We have several editions ...
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell ...
New data to be presented from Company’s lead product candidate SENTI-202 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) development program SOUTH SAN FRANCISCO, Calif., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback